` BIO (Bioton SA) vs WIG20 Comparison - Alpha Spread

B
BIO
vs
W
WIG20

Over the past 12 months, BIO has underperformed WIG20, delivering a return of +35% compared to the WIG20's +43% growth.

Stocks Performance
BIO vs WIG20

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BIO vs WIG20

Performance Gap Between BIO and WIG20
HIDDEN
Show

Performance By Year
BIO vs WIG20

Loading
BIO
WIG20
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Bioton SA vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Bioton SA
Glance View

Market Cap
324.6m PLN
Industry
Biotechnology

BIOTON SA engages in the manufacture and production of medicine and pharmaceutical substances. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 371 full-time employees. The company went IPO on 2005-03-16. The firm is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The firm's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.

BIO Intrinsic Value
HIDDEN
Show
Back to Top